Stifel sees "highly favorable" risk/reward profile for Ocera Therapeutics

Shares of Ocera Therapeutics (OCRX +7.7%) have maintained their momentum and are up sharply in afternoon trading.

Details from Stifel's coverage initiation are available.

"We believe the combination of palatable clinical development risk, steady data/news flow, strong patent estate, and potential to meaningfully improve the treatment algorithm in an already greater than $1B HE market opportunity with a rapidly expanding patient demographic creates a highly favorable risk/reward at these levels," analyst Stephen Willey says.

From other sites
Comments (1)
  • Tweetypielori
    , contributor
    Comments (6) | Send Message
    In regards to OCRX. Why has the price dropped so much in the last few weeks. I don't see the percentage in other stocks in the BIO area as much as this one. I could not find out any reason the pull back.


    Any comments would be appreciated.
    5 Feb 2014, 10:06 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs